nybanner

        News

        The successor of the blockbuster diet drug Somaglutide

        On July 27, 2023, Lilly announced that the Mount-3 study of Tirzepatide for treating obese patients and the Mount-4 study for maintaining weight loss of obese patients had reached the primary end point and the key secondary end point. This is the third and fourth successful phase III research obtained by Tirzepatide after Mount-1 and Mount-2.

        news31

        SURMOUNT-3 (NCT04657016) is a multicenter, randomized, double-blind, parallel, placebo-controlled trial enrolling a total of 806 participants designed to demonstrate Tirzepatide's superiority over placebo in terms of the percentage change in weight change after randomization and the percentage of participants who lost ≥5% after randomization at 72 weeks.

        The SURMOUNT-3 study results showed that Tirzepatide met all endpoints, namely that after 72 weeks of dosing treatment, patients in the Tirzepatide group achieved a higher percentage of weight loss from baseline compared to placebo, and a higher percentage of patients in the Tirzepatide group achieved a percentage weight loss greater than 5%. Specific clinical data showed that patients treated with Tirzepatide lost an average of 21.1% of body weight compared to placebo; Combined with the 12-week intervention period, patients treated with Tirzepatide lost an average of 26.6 percent of their body weight. In addition, 94.4% of patients lost ≥5% of their weight in the Tirzepatide group, compared with 10.7% in the placebo group.

        SURMOUNT-4 (NCT04660643) is a multicenter, randomized, double-blind, parallel, placebo-controlled trial enrolling a total of 783 participants designed to demonstrate that Tirzepatide was superior to placebo in percentage weight change at 88-week randomization.

        The results showed that after the double-blind period of 37~88 weeks, patients in the Tirzepatide group lost more weight than in the placebo group. In terms of safety, neither the SURMOUNT-3 nor SURMOUNT-4 studies observed new safety signals.

        Since the launch of Novo Nordisk's blockbuster diet drug Semaglutide, coupled with Musk's strong endorsement, it has become a phenomenal Internet celebrity product and the current weight loss king. The weight loss market demand is huge, and there are only two GLP-1 weight loss drugs currently on the market, Liraglutide and Semaglutide, but Liraglutide is a short-acting preparation, which cannot compete with long-acting preparations in terms of patient compliance, and the current weight loss world temporarily belongs to Semaglutide.

        news32

        Also the king of the GLP-1 field, Lilly covets the blue ocean of the weight loss market - so Lilly launched a challenge and first bet on Tirzepatide to seize a place in the weight loss market.

         

        Tirzepatide is a weekly GIPR/GLP-1R dual agonist, GIP (glucose-dependent insulin stimulating polypeptide) is another member of the glucagon peptide family, with the effect of promoting insulin secretion in an insulin-dependent manner and stimulating glucagon secretion in a hypoglycemic state, GIPR/GLP-1R dual agonist can produce blood sugar control, weight loss and other effects by stimulating both GIP and GLP-1 downstream pathways. Tirzepatide has been approved by the FDA in 2022-5 (trade name: Mounjaro) for use in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes.


        Post time: Sep-18-2023
        主站蜘蛛池模板: 18禁裸乳无遮挡啪啪无码免费| 久久久久亚洲AV成人无码网站| 精品乱码一区内射人妻无码 | 美女毛片一区二区三区四区| 国产精品免费av片在线观看| 一个看片免费视频www| 日韩不卡视频在线| 亚洲日韩久久综合中文字幕| 精品人妻系列无码一区二区三区| 国产免费卡一卡三卡乱码| 窝窝午夜看片国产精品人体宴| 太粗太长岳受不了了| 中文字幕视频网| 最新中文字幕在线观看| 亚洲精品成人a在线观看| 美女双腿打开让男人桶爽网站| 国产女人高潮抽搐叫床视频| 2021最新热播欧美极品| 天天澡天天碰天天狠伊人五月| 中日韩欧一本在线观看| 最近2018中文字幕2019高清| 亚洲欧美日韩一区二区三区在线| 精品久久久中文字幕二区| 国产一级大片在线观看| 99久热任我爽精品视频| 国产精品第一区揄拍无码| 9丨精品国产高清自在线看| 成人免费午间影院在线观看| 久久人人爽人人爽人人爽| 最近免费中文字幕大全高清大全1 最近免费中文字幕大全高清大全1 | 欧美怡红院成免费人忱友;| 俺去啦在线观看| 精品无码一区二区三区在线| 国产人妖另类在线二区| 精品丝袜国产自在线拍亚洲| 国产网红主播无码精品| 99香蕉国产精品偷在线观看| 学校触犯×ofthedead| 中文字幕精品一区| 日本最新免费二区三区| 亚州人成网在线播放|